Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A session reveal strong financial performance, with a 32% increase in total dispenses and 19% in paid prescriptions, despite a market decline. Management's optimistic guidance, steady OpEx, and improved fulfillment rates support growth projections. The positive outlook for IBSRELA and XPHOZAH revenues, along with strategic investments, outweigh concerns about competition and enrollment pace. Given the market cap of $1.52 billion, these factors suggest a positive stock price movement of 2% to 8% over the next two weeks.
Key Financial Performance
Total Product Revenues $93.4 million in Q1 2026, representing a 38% growth compared to $67.8 million in Q1 2025. This growth was driven by increased demand for IBSRELA.
IBSRELA Revenue $70.1 million in Q1 2026, a 58% increase compared to Q1 2025. Growth attributed to robust demand trends despite seasonal dynamics and winter storms.
XPHOZAH Revenue $23.3 million in Q1 2026, consistent with prior year revenue. Adjusted for a $3.8 million favorable adjustment in Q1 2025, paid prescriptions revenue grew 19% year-over-year.
R&D Expenses $20.2 million in Q1 2026, up from $14.9 million in Q1 2025. Increase primarily reflects development activities for the ACCEL Phase III trial for CIC.
SG&A Expenses $102.3 million in Q1 2026, up from $83.2 million in Q1 2025. Increase due to ongoing investments to drive commercialization demand and adoption of IBSRELA.
Net Loss $37.6 million in Q1 2026, compared to $41.1 million in Q1 2025. The net loss included $14.2 million in non-cash expenses from share-based compensation.
Cash, Cash Equivalents, and Short-term Investments $238.1 million as of the end of Q1 2026, reflecting financial strength.
XPHOZAH Total Dispenses and Paid Prescriptions Total dispenses increased by 32% and paid prescriptions by 19% in Q1 2026 compared to Q1 2025, despite a 10% decline in the overall prescription market.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
IBSRELA Revenue Growth: Achieved 58% year-over-year revenue growth in Q1 2026, driven by disciplined commercial execution. Positioned as a differentiated mechanism for IBS-C patients, aiming for $1 billion in annual revenue by 2029.
XPHOZAH Revenue Growth: Demand for XPHOZAH increased, with 32% growth in total dispenses and 19% growth in paid prescriptions year-over-year. Focused on ensuring patient access irrespective of payer coverage.
Pipeline Expansion: Initiated the ACCEL Phase III trial for IBSRELA targeting chronic idiopathic constipation (CIC). Enrollment expected to complete by year-end 2026, with top-line data in 2027. Pediatric studies for IBSRELA are ongoing, potentially extending patent life by 6 months.
Next-Generation NHE3 Inhibitor: Development of NHE3 inhibitor 531 is progressing through IND-enabling studies, potentially expanding into other therapeutic areas.
IBSRELA Market Position: Targeting high-writing healthcare providers responsible for 50% of IBS-C prescriptions. Leveraging partnerships like LPGA to increase patient awareness and engagement.
XPHOZAH Market Position: Broadening reach through targeted sales initiatives and cross-channel strategies. Focused on increasing HCP and patient engagement to address unmet needs in phosphorus control.
Financial Performance: Total product revenues grew 38% year-over-year to $93.4 million in Q1 2026. IBSRELA contributed $70.1 million, and XPHOZAH contributed $23.3 million. Net loss reduced to $37.6 million from $41.1 million in Q1 2025.
Debt Refinancing: Refinanced existing debt with SLR, extending maturity and interest-only period by 2 years, reducing cost of capital and annual interest expenses.
Capital Allocation Priorities: Focused on accelerating IBSRELA growth, investing in pipeline development, and maintaining financial strength. Revenue base is funding current operations and pipeline.
Leadership Expansion: Added Chief Legal Officer and Chief Medical Officer to strengthen executive team and support pipeline and commercial growth.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
IBSRELA Revenue Growth: Despite a 58% year-over-year revenue growth, the company faced temporary disruptions from two severe winter storms, which impacted demand trends in Q1 2026.
XPHOZAH Revenue and Market Challenges: XPHOZAH revenue remained consistent year-over-year, but the company had to address payer hurdles and ensure patient access irrespective of coverage. Additionally, the overall prescription market for XPHOZAH declined by 10%.
Pipeline Development Risks: The ACCEL Phase III trial for IBSRELA in chronic idiopathic constipation (CIC) is ongoing, with completion expected by year-end 2027. Delays or negative outcomes in this trial could impact the company's ability to expand its label and reach more patients.
Regulatory and Payer Hurdles: The company faces challenges in navigating payer coverage and prior authorization processes, particularly for IBSRELA and XPHOZAH, which could restrict patient access and impact revenue growth.
Increased Operational Expenses: R&D and SG&A expenses increased significantly year-over-year, reflecting investments in pipeline development and commercial execution. This could pressure profitability if revenue growth does not keep pace.
Debt and Financial Management: While the company refinanced its debt to extend maturity and reduce costs, reliance on debt financing and the need for disciplined capital allocation remain critical to maintaining financial strength.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Accelerating IBSRELA growth: Focus on driving IBSRELA as the first-line therapy following secretagogue failure. Targeting high-writing healthcare providers responsible for 50% of IBS-C prescriptions. Increasing patient activation through marketing efforts and partnerships like the LPGA. Enhancing prescription pull-through via specialty pharmacy networks.
Maintaining XPHOZAH momentum: Ensuring patient access regardless of payer coverage. Employing targeted sales initiatives and cross-channel strategies to increase HCP and patient engagement. Supporting pull-through with optimized HCP targeting and enhanced access messaging.
Pipeline expansion: Initiated the ACCEL Phase III trial for IBSRELA in chronic idiopathic constipation (CIC), with enrollment completion expected by year-end and top-line data in the second half of 2027. Ongoing pediatric program for IBSRELA to extend tenapanor's patent life. Development of next-generation NHE3 inhibitor, 531, progressing through IND-enabling studies.
Financial strength and capital allocation: Reiterating 2026 revenue guidance for IBSRELA ($410M-$430M) and XPHOZAH ($110M-$120M). Long-term growth expectation for IBSRELA to reach $1 billion in 2029. Refinanced existing debt to extend maturity, lower cost of capital, and preserve optionality for business development.
IBSRELA revenue growth: Expected to grow quarter-over-quarter for the remainder of 2026, with full-year revenue guidance between $410M and $430M, representing 50%-57% year-over-year growth. Long-term goal to achieve $1 billion in annual revenue by 2029.
XPHOZAH revenue growth: Full-year 2026 revenue guidance between $110M and $120M. Focused on ensuring access for all patients and driving growth through targeted sales initiatives.
Pipeline development timelines: ACCEL Phase III trial for IBSRELA in CIC to complete enrollment by year-end 2026, with top-line data expected in the second half of 2027. Pediatric program for IBSRELA ongoing to extend patent life. Next-generation NHE3 inhibitor, 531, progressing through IND-enabling studies.
Operational expense growth: Operational expenses expected to grow by approximately 25% in 2026, aligned with investments in commercial execution and pipeline development.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How should the increased demand for IBSRELA despite storms and seasonality flow through to the next quarters?
A:Management expects continued quarter-over-quarter growth in demand for IBSRELA, supported by strong execution and investment in access to ensure prescription fulfillment.
Q:What is the guidance for OpEx throughout 2026, considering the Phase III CIC study ramp-up?
A:The total OpEx is guided to be about $520 million, consistent throughout the quarters. The first quarter recorded $122 million, with a ramp-up expected as the Phase III CIC study progresses. This is factored into the overall guidance.
Q:Can you provide an update on the pace of enrollment for the Phase III CIC trial and learnings from the IBS-C TEMPO enrollment experience?
A:The pace of enrollment is on par with expectations from the TEMPO program. Enthusiasm from treating physicians and patients is evident, and enrollment continues at pace, aligning with the expected time frame for completion and data sharing.
Q:Should we expect a bigger recovery in IBSRELA sales in Q2 compared to last year, given the seasonality and storms in Q1?
A:Management views the Q2 performance as part of the normal course of business rather than a recovery. Despite the impact of storms in Q1, they are confident in achieving expected Q2 results.
Q:Is the shift to the IBSRELA Pharmacy Network improving fill and reauthorization rates?
A:Yes, the shift to the IBSRELA Pharmacy Network has improved fulfillment and reauthorization rates. It ensures better access for patients and leads to higher refill rates, benefiting both patients and the business.
Q:How does management view the potential impact of Lilly's GIPR agonist for IBS-C on the IBSRELA franchise?
A:Management does not see Lilly's GIPR agonist as a significant threat to the IBSRELA franchise. They believe the market positioning of IBSRELA and the relatively small percentage of patients using GLP-1s mitigate the impact.
Q:What is the current use of IBSRELA in CIC, and how does management view the competitive dynamics in this indication?
A:Physicians are prescribing IBSRELA off-label for CIC, but management does not promote off-label use. The CIC program aims to address barriers and align with the evolving definitions in Rome V. Competitive dynamics are expected to be similar to IBS-C.
Q:What is the significance of the IBSRELA pediatric trials and the potential 6-month additional patent life?
A:The pediatric trials aim to demonstrate safety and allow treatment for younger patients. The additional 6-month patent life is significant, adding incremental value based on peak revenue projections.
Q:What are the differences in physician touchpoints between CIC and IBS-C, and would the sales force need to expand for CIC?
A:CIC involves a larger patient population, with more patients treated in primary care. Management may optimize the sales force to target high-prescribing primary care physicians but does not plan to significantly expand the team.
Q:Is management willing to leverage the balance sheet for growth opportunities?
A:Management is open to leveraging the balance sheet for high-value opportunities but emphasizes the company's trajectory toward generating more top-line revenue than expenses.
Q:What is the impact of the field manager expansion on IBSRELA prescribing?
A:The expansion impacts both the breadth and depth of prescribing. Field managers help ensure prescription fulfillment, allowing sales representatives to focus on increasing new prescriptions.
Q:What is the gross-to-net (GTN) rate for IBSRELA and XPHOZAH, and how will it trend for the rest of the year?
A:The GTN rate is about 36.4% for Q1, expected to taper off in subsequent quarters. The blended total GTN rate for the year is projected to be in the low-30s.
Q:What is the long-term revenue guidance for XPHOZAH and IBSRELA?
A:The long-term revenue guidance is $750 million for XPHOZAH and $1 billion for IBSRELA.
Q:What are the growth drivers for IBSRELA, and which has the most room to grow?
A:Growth drivers include new writers, depth of prescribing, and refill rates. Management sees significant opportunities across all these areas, supported by the IBSRELA Pharmacy Network.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the pace of enrollment relative to internal expectations for the Phase III CIC trial, the ultimate potential percentage of business through the IBSRELA Pharmacy Network, and the exact gross-to-net rates for individual products. Additionally, they did not provide quarterly guidance for cash flow profitability or further granularity on IBSRELA growth between new patient starts and refill persistence trends.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ACCEL
Ardelyx
CIC effort
Dr
HCP access
IBS population
IBSRELA mechanism
III trial
LPGA
SLR
account
adoption HCPs
allocation priority
capital allocation
constipation
demand driver
depth writing
development
dispenses prescription
effectiveness
experience
fulfillment
increase dispenses
loan
maturity
need ability
patient IBS
payer coverage
period increase
potential
prescription XPHOZAH
prescription pull
priority IBSRELA
product revenue
reach
strength
symptom treatment
ARDX Transcript
Ardelyx, Inc. (ARDX) Q1 2026 Earnings Call Transcript
Positive4-30
The earnings call summary and Q&A session reveal strong financial performance, with a 32% increase in total dispenses and 19% in paid prescriptions, despite a market decline. Management's optimistic guidance, steady OpEx, and improved fulfillment rates support growth projections. The positive outlook for IBSRELA and XPHOZAH revenues, along with strategic investments, outweigh concerns about competition and enrollment pace. Given the market cap of $1.52 billion, these factors suggest a positive stock price movement of 2% to 8% over the next two weeks.
Ardelyx, Inc. (ARDX) Q4 2025 Earnings Call Transcript
Positive2-20
The earnings call reflects strong financial performance with raised revenue guidance for IBSRELA and growth expectations for XPHOZAH. The company is investing in pipeline development and commercial expansion, indicating confidence in future growth. While management avoided giving guidance on sustained cash flow positivity, they highlighted strategic investments and infrastructure sufficiency. The Q&A session reveals a focus on innovation and market expansion, with management addressing key concerns. Given the market cap of $1.52 billion, the positive guidance and strategic initiatives are likely to result in a positive stock price movement of 2% to 8% over the next two weeks.
Ardelyx, Inc. (ARDX) Q3 2025 Earnings Call Transcript
Positive10-30
The company's strong revenue guidance for IBSRELA and XPHOZAH, coupled with strategic market plans and financial flexibility, indicate positive momentum. The raised guidance for IBSRELA and the company's confidence in achieving sales targets for XPHOZAH are positive indicators. Despite a slight increase in net loss, cash reserves remain strong. The Q&A reveals confidence in market strategies and potential growth areas. The market cap suggests moderate volatility, leading to a positive prediction for stock price movement.
Ardelyx, Inc. (ARDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Neutral9-8
ARDX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
